Legal & General Group Plc lifted its stake in Radius Health, Inc. (NASDAQ:RDUS) by 14.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,372 shares of the biopharmaceutical company’s stock after purchasing an additional 1,697 shares during the period. Legal & General Group Plc’s holdings in Radius Health were worth $605,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RDUS. BlackRock Inc. increased its holdings in shares of Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after purchasing an additional 2,628,070 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Radius Health by 67.8% in the first quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock valued at $17,163,000 after purchasing an additional 179,471 shares in the last quarter. Pictet Asset Management Ltd. increased its holdings in shares of Radius Health by 20.0% in the second quarter. Pictet Asset Management Ltd. now owns 641,388 shares of the biopharmaceutical company’s stock valued at $22,205,000 after purchasing an additional 106,849 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Radius Health by 3.2% in the first quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock valued at $116,362,000 after purchasing an additional 93,188 shares in the last quarter. Finally, TD Asset Management Inc. increased its holdings in shares of Radius Health by 68.0% in the second quarter. TD Asset Management Inc. now owns 145,970 shares of the biopharmaceutical company’s stock valued at $6,602,000 after purchasing an additional 59,100 shares in the last quarter.

In other Radius Health news, major shareholder Growth N. V. Biotech purchased 60,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was purchased at an average cost of $35.98 per share, for a total transaction of $2,158,800.00. Following the transaction, the insider now owns 5,248,799 shares in the company, valued at approximately $188,851,788.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 150,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 469,100 shares of company stock valued at $16,328,382. Corporate insiders own 15.00% of the company’s stock.

A number of analysts recently weighed in on the stock. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. BidaskClub cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $38.00 price objective (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.60.

Radius Health, Inc. (NASDAQ RDUS) opened at 38.48 on Friday. The company’s market capitalization is $1.67 billion. The firm has a 50-day moving average of $36.49 and a 200-day moving average of $38.70. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $55.97.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the prior year, the business posted ($1.01) EPS. Equities analysts expect that Radius Health, Inc. will post ($5.58) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Legal & General Group Plc Raises Position in Radius Health, Inc. (RDUS)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/06/legal-general-group-plc-raises-position-in-radius-health-inc-rdus.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.